Printer Friendly

COGNEX TREATMENT IND PROGRAM ENTERS SECOND PHASE 15,000 EXPECTED TO MAKE USE OF EXPERIMENTAL THERAPY

COGNEX TREATMENT IND PROGRAM ENTERS SECOND PHASE 15,000 EXPECTED TO MAKE
 USE OF EXPERIMENTAL THERAPY
 MORRIS PLAINS, N.J., Aug. 11 /PRNewswire/ -- The Parke-Davis division of Warner-Lambert Company (NYSE: WLA) announced today that it has achieved its goal of enrolling 1,500 physicians in the Cognex Treatment IND (known as the Cognex Access Program), and is now focusing its efforts on patient enrollment.
 CAP expands access to Cognex (tacrine/THA), an experimental drug being studied for the treatment of the symptoms of Alzheimer's disease. As many as 15,000 patients will be enrolled in the program.
 Through a Treatment IND, the Food and Drug Administration allows certain unapproved drugs that have shown some evidence of effectiveness to be used by desperately ill patients where no other treatment is available.
 "The program expands access to Cognex while allowing Parke-Davis to collect additional safety data," said Dr. Fred Hershenson, senior vice president, technical development.
 Patients are given weekly blood tests because Cognex causes liver function abnormalities in some patients which may lead to toxicity. If at any time during the program a patient exhibits elevated liver enzymes, drug therapy is reevaluated.
 A special program has been set up to provide the drug at no charge to those who cannot afford it.
 For those interested in participating in the Treatment IND program, a toll-free telephone number has been set up to answer questions and facilitate enrollment. Patients, caregivers and physicians interested in the program can call 1-800-452-6463.
 Alzheimer's Disease Little Understood
 While the cause of the disease is unknown, scientists have discovered that patients diagnosed with Alzheimer's have a deficiency of the neurotransmitter acetylcholine, one of several chemicals that carry messages between cells in the brain.
 The cholinergic system -- the neurological apparatus in which acetylcholine works -- is thought to be responsible for memory, perception, learning and other higher mental functions -- the key brain functions affected by Alzheimer's disease. It is not known whether acetylcholine-deficiency is a cause of Alzheimer's disease or a consequence.
 Scientists hypothesize that Cognex prevents the destruction of acetylcholine, thus slowing cognitive decline. Cognex is being studied to see if it has any effect on the debilitating symptoms of Alzheimer's such as memory loss and the inability to perform daily activities.
 Alzheimer's Disease
 Alzheimer's disease afflicts 4 million Americans, with the greatest incidence among those over age 65. Approximately 10 percent of people over age 65 and 47 percent over age 85 have the disease. By the middle of the 21st century, as many as 14 million Americans will have it, according to the National Institute on Aging.
 One of the leading causes of dementia and the fourth leading cause of death in adults, Alzheimer's disease is a progressive brain disorder that impairs memory and thinking, and results in personality changes and physical deterioration. Progression of the disease is judged, in part, by cognitive function decline.
 Cognitive decline, the most prevalent and incapacitating symptom of Alzheimer's, is evidenced by some combination of memory loss, impaired intellect, speech disturbances, inability to interact socially, depression and neuromuscular changes.
 -0- 8/11/92
 /CONTACT: Peter Wolf of Warner-Lambert, 201-540-6696, or


Gianfranco Chicco of Burson-Marsteller, 212-614-5125, for Warner-Lambert/
 (WLA) CO: Warner-Lambert Company ST: New Jersey IN: MTC SU:


LR -- NY046 -- 8976 08/11/92 12:34 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 1992
Words:544
Previous Article:SYNTELLECT PROMOTES PREDOVIC TO CFO, COMPANY SECRETARY; NEW CHARTER INCLUDES OVERSEEING ACQUISITIONS, MAINTAINING COMPANY GROWTH
Next Article:SANDOZ LICENSES OVALTINE IN U.S. TO HIMMEL
Topics:


Related Articles
WARNER-LAMBERT REPORTS RECORD SALES AND EARNINGS IN SECOND QUARTER
WARNER-LAMBERT ISSUES STATEMENT ON TACRINE STUDY IN NEW ENGLAND JOURNAL
WARNER-LAMBERT ISSUES STATEMENT ON TACRINE STUDY IN NEW ENGLAND JOURNAL
NEW CLINICAL TRIAL DATA FOR ALZHEIMER'S DRUG COGNEX PRESENTED TO FDA ADVISORY COMMITTEE
FIRST U.S. DRUG TO TREAT ALZHEIMER'S DISEASE CLEARED FOR MARKETING
BURROUGHS WELLCOME MAKES INVESTIGATIONAL LUNG CANCER DRUG WIDELY AVAILABLE
CELL GENESYS COMPLETES ENROLLMENT IN T CELL GENE THERAPY TRIAL FOR AIDS
GUILFORD PHARMACEUTICALS FILES TREATMENT IND FOR GLIADEL
CELL GENESYS FILES IND FOR EXPANDED AIDS GENE THERAPY TRIALS
Transkaryotic Therapies' Partner, Hoechst Marion Roussel, Files IND To Commence Clinical Trial For Gene Activated Erythropoietin

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters